Search Results
Your search for A matches 32982 pages
Showing 6151 - 6200TROPiCS-02 Sacituzumab Govitecan Effective in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
For advanced breast cancer that is hormone receptor–positive and HER2-negative, sacituzumab govitecan-hziy significantly reduced the risk of disease progression by 34% over physician’s choice of treatment, based on the results of the phase III TROPiCS-02 trial.1 The heavily pretreated patients in...
Expert Point of View: Kimmie Ng, MD, MPH
The study’s invited discussant was Kimmie Ng, MD, MPH, Associate Professor of Medicine at Harvard Medical School and Co-Director of the Colon and Rectal Cancer Center at Dana-Farber Cancer Institute, Boston. “Neoadjuvant dostarlimab-gxly for 6 months represents a promising new treatment for...
100% Complete Response Rate in 14 Patients With Rectal Cancer Treated With Neoadjuvant Dostarlimab-gxly
In a study of 18 patients with locally advanced mismatch repair–deficient (dMMR) rectal cancer, 6 months of neoadjuvant treatment with the anti–PD-1 agent dostarlimab-gxly alone led to clinical complete responses in 100% of the study’s first 14 patients.1 These results were presented at the 2022...
Expert Point of View: Patricia LoRusso, DO, PhD
Invited discussant Patricia LoRusso, DO, PhD, of Yale School of Medicine, said to the assembled audience at the 2022 ASCO Annual Meeting: “I see you are as excited about these data as I am,” after the applause ended following Dr. Modi’s presentation. “I want to thank our colleagues for helping to...
DESTINY-Breast04 Trial: T-DXd Significantly Improves Survival in Patients With HER2-Low Metastatic Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) doubled progression-free survival compared with chemotherapy alone in patients with “HER2-low” metastatic breast cancer—ie, patients with low levels of HER2 expression. The agent also extended overall survival for patients with low ...
Expert Point of View: Guru P. Sonpavde, MD
Guru P. Sonpavde, MD, Director of the Bladder Cancer Program at Dana-Farber Cancer Institute and a faculty member of Harvard Medical School, Boston, said these follow-up data from CheckMate 274 provide reassurance that the disease-free survival benefit is maintained with adjuvant nivolumab. “We...
CheckMate 274: Adjuvant Immunotherapy Improves Disease-Free Survival in Metastatic Urothelial Cancer
Adjuvant nivolumab could become the standard of care for patients with metastatic bladder cancer, according to data presented at the American Urological Association (AUA) 2022 Annual Meeting.1 With longer follow-up, the results of the phase III CheckMate 274 trial showed that treatment with the...
Mismatch in Breast Cancer Trial Results and Real-World Outcomes Based on Treatment Discontinuation
New research published by Zeng et al in JNCCN—Journal of the National Comprehensive Cancer Network raises issues with clinical trial findings that show adjuvant hormone therapy–related hot flashes predict better treatment outcomes among patients with estrogen receptor–positive breast cancer. The...
Study Links Sugar-Sweetened Beverage Consumption and Liver Cancer Risk
A study of more than 90,000 postmenopausal women found that those who consumed at least one sugar-sweetened beverage daily faced a 78% higher risk of developing liver cancer compared with people who consumed less than three servings per month of such beverages. These findings were presented by Zhao ...
Study Examines How Diet Quality May Affect Breast Cancer Risk
Research shows that what we eat may influence our cancer risk, but it’s not always clear which foods or dietary patterns are best for cancer prevention. Results from a new study presented by Shah et al during Nutrition 2022 Live Online, the annual meeting of the American Society for Nutrition,...
Factors That May Predict Response to the Addition of Bevacizumab to Front-Line Chemotherapy in Patients With Endometrial Cancer
In an analysis from an NRG Oncology/Gynecologic Oncology Group phase II study (GOG-86P) reported in the Journal of Clinical Oncology, Thiel et al looked at outcomes in patients with advanced endometrial cancer treated with bevacizumab added to front-line chemotherapy. The investigators found that...
Gilberto de Lima Lopes, Jr, MD, MBA, and Oladimeji Akinboro, MD, MPH, on NSCLC: Outcomes of Anti–PD-(L)1 Therapy With or Without Chemotherapy in the First-Line Setting
Gilberto de Lima Lopes, Jr, MD, MBA, of Sylvester Comprehensive Cancer Center at the University of Miami, and Oladimeji Akinboro, MD, MPH, of the U.S. Food and Drug Administration (FDA), discuss a data analysis, which suggests that most subgroups of patients with advanced non–small cell lung cancer ...
New Perspective Shows Higher Breast Cancer Mortality for Black Women Emerged 40 Years Ago
A new perspective piece authored by researchers from the American Cancer Society and The University of Texas Health Science Center at San Antonio shows the high burden of breast cancer mortality among Black women as compared to White women began in the United States in the 1980s. At that time,...
Study Identifies Three-Gene Signature That May Predict Response to Selinexor in Patients With Multiple Myeloma
Researchers have, for the first time, identified genes that may predict response to a therapy for a blood cancer that can have serious side effects for some patients. The therapy, selinexor, is part of the treatment armamentarium for multiple myeloma, but the ability to target its use to patients...
Does Receipt of Adjuvant Chemotherapy After Primary Retroperitoneal Lymph Node Dissection Affect Outcomes for Patients With Nonseminomatous Germ Cell Tumors?
In a single-institution study reported in the Journal of Clinical Oncology, Tachibana et al found high recurrence-free survival rates among patients with pathologic stage II nonseminomatous germ cell tumors who underwent primary retroperitoneal lymph node dissection and who did not receive adjuvant ...
Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer in Persons With HIV
In the phase III ANCHOR study reported in The New England Journal of Medicine, Palefsky et al found that treatment of high-grade squamous intraepithelial lesions was successful in preventing anal cancer vs active monitoring in persons infected with HIV. Study Details In the multicenter trial, 4,446 ...
Cabozantinib and Atezolizumab for Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Post–Hormonal Therapy
As reported in The Lancet Oncology by Neeraj Agarwal, MD, and colleagues, findings in the expansion cohort of the phase Ib COSMIC-021 trial indicate activity of the combination of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer whose disease progressed ...
Four New Teams Receive $100M to Take on Cancer's Toughest Challenges
Representing a total investment of $100 million, the following teams are the first to be funded through the partnership between Cancer Research UK and the National Cancer Institute in the United States. These teams join the Cancer Grand Challenges community, which now unites more than 700...
Martin McCabe, PhD, on Ewing Sarcoma: Assessment of Topotecan, Cyclophosphamide, and High-Dose Ifosfamide
Martin McCabe, PhD, of the University of Manchester, discusses a phase III assessment of chemotherapy for patients with recurrent and primary refractory Ewing sarcoma. The trial, called rEECur, is the first study to provide comparative toxicity and survival data for the four most commonly used...
Etienne Brain, MD, PhD, on Breast Cancer: Adjuvant Endocrine Therapy With or Without Chemotherapy in Older Patients
Etienne Brain, MD, PhD, of the Institut Curie, discusses phase III findings from the Unicancer ASTER 70s trial, in which patients aged 70 or older with estrogen receptor–positive, HER2-negative breast cancer and a high genomic grade index received adjuvant endocrine therapy with or without...
An Oncology Surgeon Leads Mexico’s Melanoma Program
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with surgical oncologist Héctor Martínez-Said, MD, of the Melanoma Clinic at NCI Mexico. Dr. Martínez-Said’s maternal grandfather was part of a Lebanese immigration movement...
Study Finds Diagnostic Mammography Performance Varies Across Racial and Ethnic Groups
The disparities in female breast cancer incidence and mortality among racial and ethnic groups is well documented. Studies show that while Black women have a lower incidence of breast cancer compared with White women, they are 41% more likely to die from the disease than White women. Breast cancer...
Are Virtual Frailty Assessments for Older Patients With Hematologic Malignancies Effective?
According to a study published by DuMontier et al in the journal Blood Advances, frailty assessments—geriatric exams considered essential to predicting health outcomes in older adults with cancer—are both safe and feasible when conducted virtually for patients with blood cancers. While providers...
Germline Variants in Types of Cancer Without Hereditary Testing Guidelines
In a study reported in JAMA Network Open, Timothy A. Yap, MBBS, PhD, FRCP, and colleagues found that a substantial proportion of patients with cancer types that lacked hereditary testing guidelines harbored germline pathogenic/likely pathogenic variants. Study Details The study included data from...
MMP-7 Expression and Pathologic Response to Neoadjuvant Treatment in Patients With Pancreatic Cancer Undergoing Resection
In a single-institution study reported in JAMA Surgery, Shoucair et al found that matrix metalloproteinase 7 (MMP-7) expression in fine-needle aspiration biopsy specimens was associated with pathologic response to neoadjuvant therapy in patients undergoing resection for pancreatic ductal...
Overall Survival in Patients With Metastatic Colorectal Cancer in Phase III Trials and SEER Database Over a 30-Year Period
In a study reported in JAMA Network Open, Shen et al found that data from both phase III trials and the Surveillance, Epidemiology, and End Results (SEER) database indicate significant improvements in overall survival for patients with metastatic colorectal cancer over a 30-year period. Increases...
William Catalona, MD, on the Evolution of Views Regarding Active Surveillance in Men With Low-Risk Prostate Cancer
William Catalona, MD, Professor of Urology at Northwestern University’s Feinberg School of Medicine, and past Principal Investigator on the Northwestern-based prostate SPORE, explained the evolution of his views regarding active surveillance in men with low-risk prostate cancer. Although...
Rates of Active Surveillance Rising Among Men With Low-Risk Prostate Cancer but Still Suboptimal
Most men with low-risk prostate tumors now opt for active surveillance, but overtreatment remains a problem, according to data presented during the 2022 American Urological Association (AUA) Annual Meeting.1 A retrospective analysis of more than 20,000 patients with low-risk prostate cancer showed...
Looking Back at Telemedicine During the COVID-19 Era: Lessons Learned and Disparities Identified
Telemedicine stepped up to the plate when the COVID-19 pandemic swept the globe. Oncology providers—and practitioners in all specialties—had to rapidly adapt to a telemedicine format when face-to-face visits were severely limited. This scenario had its benefits for both patients and providers (and...
Study Investigates Rural/Urban Disparities in Hospice Care Among Patients With Hematologic Malignancies
People with blood cancers living in rural areas are less likely to receive end-of-life hospice care compared to those living in metropolitan regions, according to a new study published by Hussaini et al in the journal Blood Advances. In this study, researchers identified significant disparities in...
FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children as Young as 6 Months of Age
On June 17, the U.S. Food and Drug Administration (FDA) authorized emergency use of the Moderna COVID-19 vaccine and the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 to include use in children as young as 6 months of age. For the Moderna vaccine, the FDA amended the emergency...
Postmarketing Ocular Toxicity in U.S. Adults Treated With Daratumumab
In an analysis reported in a research letter in JAMA Oncology, Nguyen et al identified postmarketing cases of ocular toxicity in patients receiving daratumumab in the United States. Daratumumab is a CD38-directed monoclonal antibody that was initially approved in 2015 for the treatment of multiple...
MRD-Guided Cessation of Treatment in Patients Receiving Venetoclax/Ibrutinib for Relapsed or Refractory CLL
In a phase II trial (HOVON141/VISION) reported in The Lancet Oncology, Arnon P. Kater, MD, PhD, and colleagues found a high rate of 12-month progression-free survival among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who stopped venetoclax/ibrutinib after achieving...
Ann H. Partridge, MD, MPH, and Ian E. Krop, MD, PhD, on Metastatic Breast Cancer: New Early Data on Patritumab Deruxtecan
Ann H. Partridge, MD, MPH, Dana-Farber Cancer Institute, and Ian E. Krop, MD, PhD, of Yale Cancer Center, discuss phase I/II findings on patritumab deruxtecan, a HER3-directed antibody-drug conjugate, in patients with HER3-expressing metastatic breast cancer. A pooled analysis showed antitumor...
Relapsed/Refractory Hodgkin Lymphoma
This is Part 4 of Updates in Lymphoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alison J. Moskowitz, Andrew M. Evens, and Ann S. LaCasce discuss the management of relapsed/refractory Hodgkin lymphoma. The patient is a...
Hodgkin Lymphoma in Patients Age ≥ 60 Years
This is Part 3 of Updates in Lymphoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alison J. Moskowitz, Andrew M. Evens, and Ann S. LaCasce discuss Hodgkin lymphoma in patients age ≥ 60 years. The patient is a 65-year-old man...
Bulky Early-Stage Hodgkin Lymphoma
This is Part 2 of Updates in Lymphoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alison J. Moskowitz, Andrew M. Evens, and Ann S. LaCasce discuss the management of bulky early-stage Hodgkin lymphoma. The patient is a...
Advanced-Stage Hodgkin Lymphoma
This is Part 1 of Updates in Lymphoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alison J. Moskowitz, Andrew M. Evens, and Ann S. LaCasce discuss the management of advanced-stage Hodgkin lymphoma. The patient is a...
Apar Kishor Ganti, MD, on SCLC: Comparing Quality of Life With Once- and Twice-Daily Thoracic Radiotherapy
Apar Kishor Ganti, MD, of the University of Nebraska Medical Center, discusses results from the CALGB 30610 study, which showed a similar clinical benefit for once- and twice-daily radiotherapy administered to patients with limited-stage small cell lung cancer. While both regimens were well...
Eunice S. Wang, MD, on AML: Long-Term Results With Crenolanib Plus Chemotherapy
Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discusses long-term phase II findings of a trial evaluating crenolanib plus chemotherapy in newly diagnosed adults with FLT3-mutant acute myeloid leukemia. The study showed a composite complete remission rate of 86%. With a median...
Elevating Cancer Care in the United States for All: Current Challenges and Potential Solutions
Optimizing oncology care in the United States will require making state-of-the-art care more accessible to all. Delivering quality, equitable cancer care is undoubtedly a challenge in a country as large, diverse, and disparate as the United States, but if it is to be achieved, it will entail the...
Androgen Receptor Signaling May Contribute to Targeted Therapy Resistance in Patients With Melanoma
Androgen receptor (AR) signaling may affect response to BRAF/MEK inhibitor therapy in both male and female patients with melanoma, according to findings from a study published by Vellano et al in Nature. The report provides a new target to combat therapeutic resistance and one possible answer to...
Can Abemaciclib Provide Good Clinical Outcomes in Patients With High-Risk Hormone Receptor–Positive, HER2-Negative Breast Cancer Who Received Neoadjuvant Chemotherapy?
In a prespecified analysis from the phase III monarchE trial reported in JAMA Oncology, Miguel Martín, MD, PhD, and colleagues found that the addition of adjuvant abemaciclib to endocrine therapy was associated with improved outcomes among women with high-risk hormone receptor–positive,...
Real-World Association Between Smoking History and Overall Survival With First-Line Pembrolizumab in Patients With Advanced NSCLC
In a retrospective cohort study reported in JAMA Network Open, Sanjay Popat, FRCP, PhD, and colleagues found that among patients initiating first-line pembrolizumab for EGFR and ALK wild-type advanced non–small cell lung cancer (NSCLC), ever-smokers had significantly better overall survival vs...
Survival With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy in Patients With SCLC and Intracranial Metastatic Disease
In a systematic review and meta-analysis reported in The Lancet Oncology, Gaebe et al found that stereotactic radiosurgery (SRS) was associated with “equitable survival” compared with whole-brain radiotherapy (WBRT) in the first-line treatment of intracranial metastatic disease in patients with...
Study Finds Adult Survivors of Childhood Cancer May Often Be Undertreated for Modifiable Cardiovascular Risk Factors
Adults who survive childhood cancer have a higher risk of cardiovascular disease than the general population, yet they are 80% more likely to be undertreated for several cardiovascular risk factors, such as hypertension, diabetes, and high cholesterol, according to new research published by Eric J. ...
Demethylation and Upregulation of the Oncogene SALL4 After Hypomethylating Therapy
In a study reported in The New England Journal of Medicine, Liu et al found that hypomethylating therapy was associated with upregulation of the oncogene SALL4 in a high proportion of patients with myelodysplastic syndrome. They also identified the gene region that is demethylated and responsible...
Potential Association of the 2012 USPSTF Grade D Recommendation Against PSA Screening With Changes in Prostate Cancer–Specific Mortality
In a study reported in JAMA Network Open, Burgess et al found that the 2012 U.S. Preventive Services Task Force (USPSTF) Grade D recommendation against prostate-specific antigen (PSA) screening for all men appeared to be associated with ending of a trend of annual reductions in prostate...
Proposed Second Revision of the International Staging System for Survival in Multiple Myeloma
As reported in the Journal of Clinical Oncology by D’Agostino et al in the European Myeloma Network, a second revision (R2-ISS) of the Revised International Staging System (R-ISS) incorporates a risk scoring system that permits delineation of four prognostic risk groups in newly diagnosed multiple...
Risk of Skin Desquamation With Breast Radiotherapy: Does Position Change Outcomes in Large-Breasted Women?
In a Canadian phase III trial reported in JAMA Oncology, Vesprini et al found that receipt of adjuvant breast radiotherapy in the supine position was associated with increased risk of moist desquamation of skin vs receipt in the prone position among large-breasted women with breast cancer. Study...
